Cyclo Therapeutics (CYTH)
(Delayed Data from NSDQ)
$1.08 USD
-0.02 (-1.82%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.11 +0.03 (2.78%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Cyclo Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -20.06 | -15.45 | -14.29 | -8.94 | -7.53 |
Depreciation/Amortization & Depletion | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 |
Net Change from Assets/Liabilities | 3.06 | -0.05 | -1.23 | 0.12 | 1.10 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.79 | 0.37 | 0.49 | 0.27 | -0.16 |
Net Cash From Operating Activities | -16.19 | -15.11 | -15.01 | -8.54 | -6.59 |
Property & Equipment | 0.00 | -0.02 | -0.02 | -0.05 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.05 | 0.04 | 0.04 | 0.04 |
Net Cash from Investing Activities | 0.00 | 0.04 | 0.01 | -0.01 | 0.04 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 14.54 | 0.00 | 18.76 | 18.46 | 6.99 |
Issuance (Repayment) of Debt | 0.00 | 0.01 | -0.01 | 0.16 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 9.35 | 0.00 | 0.00 | 0.00 | 0.13 |
Net Cash from Financing Activities | 23.89 | 0.01 | 18.76 | 18.62 | 7.12 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 7.70 | -15.07 | 3.77 | 10.06 | 0.57 |
Cash at Beginning of Period | 1.54 | 16.61 | 12.85 | 2.78 | 2.22 |
Cash at End of Period | 9.25 | 1.54 | 16.61 | 12.85 | 2.78 |
Diluted Net EPS | -1.23 | -1.83 | -2.24 | -5.60 | -7.00 |
Fiscal Year End for Cyclo Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -4.34 | -20.06 | -14.41 | -9.64 |
Depreciation/Amortization & Depletion | NA | 0.00 | 0.02 | 0.01 | 0.01 |
Net Change from Assets/Liabilities | NA | -2.12 | 3.06 | 2.03 | 1.51 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 0.28 | 0.79 | 0.48 | 0.28 |
Net Cash From Operating Activities | NA | -6.18 | -16.19 | -11.89 | -7.85 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.00 | 14.54 | 12.15 | 7.15 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.07 | 9.35 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | -0.07 | 23.89 | 12.15 | 7.15 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -6.25 | 7.70 | 0.26 | -0.70 |
Cash at Beginning of Period | NA | 9.25 | 1.54 | 1.54 | 1.54 |
Cash at End of Period | NA | 3.00 | 9.25 | 1.80 | 0.84 |
Diluted Net EPS | NA | -0.15 | -0.15 | -0.29 | -0.33 |